Low-Grade Serous Ovarian Cancer — 5-Minute Journal Club: Microlearning Activity 1

Featuring perspectives from Dr Rachel N Grisham, including the following topics:

• Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00)
• A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11)
• Current and future role of avutometinib with defactinib for LGSOC (19:23)
• A Phase II/III trial of trametinib for recurrent LGSOC: Biomarker analyses and clinical implications (21:37)

CME information and select publications